Skip to main content
NCBI home page
The Western Journal of Medicine logoLink to The Western Journal of Medicine
. 1989 Nov;151(5):556–558.

Intestinal pseudo-obstruction related to using verapamil.

H S Schultz, B Vernon
PMCID: PMC1026807  PMID: 2603423

Full text

PDF
556

Images in this article

556Image
on p.556

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beleslin D. B., Samardzić R., Terzić B., Jovanović-Mićić D. The effect of nifedipine and verapamil on the pendular movements of the rabbit isolated ileum. J Pharm Pharmacol. 1985 Apr;37(4):276–277. doi: 10.1111/j.2042-7158.1985.tb05062.x. [DOI] [PubMed] [Google Scholar]
  2. Coruzzi G., Poli E. The stimulatory action of the calcium channel agonist Bay K 8644 on isolated duodenal muscle. Antagonism by nifedipine and verapamil. Naunyn Schmiedebergs Arch Pharmacol. 1985 Nov;331(2-3):290–292. doi: 10.1007/BF00634251. [DOI] [PubMed] [Google Scholar]
  3. Hedbäck B., Hermann L. S. Antihypertensive effect of verapamil in patients with newly discovered mild to moderate essential hypertension. Acta Med Scand Suppl. 1984;681:129–135. doi: 10.1111/j.0954-6820.1984.tb08687.x. [DOI] [PubMed] [Google Scholar]
  4. Krebs R. Adverse reactions with calcium antagonists. Hypertension. 1983 Jul-Aug;5(4 Pt 2):II125–II129. doi: 10.1161/01.hyp.5.4_pt_2.ii125. [DOI] [PubMed] [Google Scholar]
  5. Lewis G. R. Long-term results with verapamil in essential hypertension and its influence on serum lipids. Am J Cardiol. 1986 Feb 26;57(7):35D–38D. doi: 10.1016/0002-9149(86)90803-9. [DOI] [PubMed] [Google Scholar]
  6. Mitchell L. B., Schroeder J. S., Mason J. W. Comparative clinical electrophysiologic effects of diltiazem, verapamil and nifedipine: a review. Am J Cardiol. 1982 Feb 18;49(3):629–635. doi: 10.1016/s0002-9149(82)80022-2. [DOI] [PubMed] [Google Scholar]
  7. Nontakanun S., Ngarmukos P., Sitthisook S., Jeam-Anukulkit N., Intharakoses A., Tanprasert P., Sansanayudth P., Sriratanaban A., Polsi Y. A multicenter study of verapamil in systemic hypertension in Thailand. Am J Cardiol. 1986 Feb 26;57(7):106D–107D. doi: 10.1016/0002-9149(86)90818-0. [DOI] [PubMed] [Google Scholar]
  8. Rinkenberger R. L., Prystowsky E. N., Heger J. J., Troup P. J., Jackman W. M., Zipes D. P. Effects of intravenous and chronic oral verapamil administration in patients with supraventricular tachyarrhythmias. Circulation. 1980 Nov;62(5):996–1010. doi: 10.1161/01.cir.62.5.996. [DOI] [PubMed] [Google Scholar]
  9. Shah M. H., Dikshit R. K., Mansuri S. M. The calcium channel antagonist, verapamil, potentiates the inhibitory action of morphine on intestinal and biliary motility. J Pharm Pharmacol. 1987 Dec;39(12):1037–1038. doi: 10.1111/j.2042-7158.1987.tb03157.x. [DOI] [PubMed] [Google Scholar]
  10. Ward D. J., Ward J. W., Griffo W., Rochwarge A. Intravenous calcium for fecal impaction secondary to verapamil. N Engl J Med. 1982 Dec 30;307(27):1709–1710. doi: 10.1056/nejm198212303072717. [DOI] [PubMed] [Google Scholar]
  11. Weiner D. A., Klein M. D. Verapamil therapy for stable exertional angina pectoris. Am J Cardiol. 1982 Nov;50(5):1153–1157. doi: 10.1016/0002-9149(82)90436-2. [DOI] [PubMed] [Google Scholar]
  12. Zinner M. J., Sherlock D., Ferrara A., McFadden D., Wait R. B., Jaffe B. M. Verapamil inhibition of the intestinal effects of substance P. Surgery. 1985 Aug;98(2):230–235. [PubMed] [Google Scholar]

Articles from Western Journal of Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES